Study Identifies Predictive Tools to Shorten Active Surveillance Required in Prostate Cancer
Source: Pixabay

Study Identifies Predictive Tools to Shorten Active Surveillance Required in Prostate Cancer

PracticeUpdate recently published an article relating to a study with the primary goal of lightening the burden that many males experience regarding long-term prostate surveillance. Active surveillance has been preferred…

Continue Reading Study Identifies Predictive Tools to Shorten Active Surveillance Required in Prostate Cancer
Experimental Treatment for Fabry Disease to be Made Available Under Expanded Access
source: pixabay.com

Experimental Treatment for Fabry Disease to be Made Available Under Expanded Access

According to a story from PR Newswire, Chiesi Global Rare Diseases and the biopharmaceutical company Protalix BioTherapeutics, Inc. have recently announced that they have launched an Expanded Access Program (EAP)…

Continue Reading Experimental Treatment for Fabry Disease to be Made Available Under Expanded Access
Potential Osteogenesis Imperfecta Treatment Receives Rare Pediatric Disease Designation
source: pixabay.com

Potential Osteogenesis Imperfecta Treatment Receives Rare Pediatric Disease Designation

According to a story from BioSpace, the biopharmaceutical company Mereo BioPharma Group recently announced that its investigational therapy setrusumab has earned Rare Pediatric Disease designation from the US Food and…

Continue Reading Potential Osteogenesis Imperfecta Treatment Receives Rare Pediatric Disease Designation

New Investigative Therapy for Myelofibrosis Patients with Severe Thrombocytopenia is Making Headway

CTI BioPharma has just announced that they are submitting a NDA for Pacritinib as a new option for myelofibrosis patients who are facing severe thrombocytopenia. The thrombocytopenia is a result…

Continue Reading New Investigative Therapy for Myelofibrosis Patients with Severe Thrombocytopenia is Making Headway
Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA
https://pixabay.com/en/baby-child-cute-doll-expression-17366/

Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA

Recently, the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") announced the FDA approval of Simponi Aria (golimumab). The therapy is designed to treat pediatric patients (ages 2 or older)…

Continue Reading Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA

The aHUS Foundation has Created a Medical Tracker for atypical Hemolytic Uremic Syndrome Patients

aHUS Tracking Atypical hemolytic uremic syndrome (aHUS) is a rare disease that causes blood clots to form within the small blood vessels in the kidneys. These clots lead to organ damage…

Continue Reading The aHUS Foundation has Created a Medical Tracker for atypical Hemolytic Uremic Syndrome Patients
Genomic Testing for Rare Cancers
source: pixabay.com

Genomic Testing for Rare Cancers

According to an article from BioSpace, the TargetCancer Foundation has began enrolling patients in their TRACK study. This study is intended to provide rare cancer patients with individualized treatment options…

Continue Reading Genomic Testing for Rare Cancers
 Pneumonia Has Been Replaced by Sepsis as the Most Common Serious Infection in Vasculitis Hospitalizations
source: pixabay.com

 Pneumonia Has Been Replaced by Sepsis as the Most Common Serious Infection in Vasculitis Hospitalizations

Dr. Jasvinder Singh, a rheumatologist at Alabama’s University in Birmingham is the author of a study that was featured in Arthritis Care and Research. During a recent interview with MedPageToday,…

Continue Reading  Pneumonia Has Been Replaced by Sepsis as the Most Common Serious Infection in Vasculitis Hospitalizations